Celgene Sues Americord Over Stem Cell Marketing

Law360, New York (April 29, 2011, 1:28 PM EDT) -- Celgene Corp. filed a lawsuit in New Jersey federal court Wednesday accusing Americord Registry LLC of copyright infringement and unfair competition for claiming to be the first company to offer placenta stem cell preservation, a distinction Celgene claims for itself.

Celgene lodged a complaint alleging Americord falsely markets itself as the first company to harvest stem cells from the placenta and umbilical blood, even though Celegene unit LifebankUSA in fact pioneered the process.

Stems cells obtained from the placenta and cord blood are valuable because they...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.